Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CYP2C19 Gene Profiling as a Tool for Personalized Stress Ulcer Prophylaxis With Proton Pump Inhibitors in Critically Ill Patients - Recommendations Proposal

P. Bořilová Linhartová, O. Zendulka, J. Janošek, N. Mlčůchová, M. Cvanová, Z. Daněk, R. Kroupa, L. Bartošová, B. Lipový

. 2022 ; 9 (-) : 854280. [pub] 20220711

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023741

To this date, there are no recommendations for personalized stress ulcer prophylaxis (SUP) in critical care that would take the patient's individual genetic predispositions into account. Of drugs used for this purpose, proton pump inhibitors (PPIs) are the first-choice drugs in intensive care unit patients. The degradation of proton pump inhibitors is mediated by cytochrome P450 (CYP) enzymes; in particular, CYP2C19 and, to a lesser extent, CYP3A4 are involved. Expression and metabolic activity of, namely in, CYP2C19 is significantly affected by single nucleotide polymorphisms, the drug metabolization rate varies greatly from ultrarapid to poor and likely influences the optimal dosage. As these CYP2C19 predictive phenotypes via CYP2C19 haplogenotypes (rs12248560/rs4244285) can be relatively easily determined using the current standard equipment of hospital laboratories, we prepared a set of recommendations for personalized PPI-based stress ulcer prophylaxis taking into account the patient's CYP2C19 predictive phenotype determined in this way. These recommendations are valid, in particular, for European, American and African populations, because these populations have the high representations of the CYP2C19*17 allele associated with the overexpression of the CYP2C19 gene and ultrarapid degradation of PPIs. We propose the CYP2C19 gene profiling as a tool for personalized SUP with PPI in critically ill patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023741
003      
CZ-PrNML
005      
20221031095104.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2022.854280 $2 doi
035    __
$a (PubMed)35899207
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bořilová Linhartová, Petra $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia $u Clinic of Maxillofacial Surgery, Faculty of Medicine, Institution Shared With University Hospital Brno, Masaryk University, Brno, Czechia
245    10
$a CYP2C19 Gene Profiling as a Tool for Personalized Stress Ulcer Prophylaxis With Proton Pump Inhibitors in Critically Ill Patients - Recommendations Proposal / $c P. Bořilová Linhartová, O. Zendulka, J. Janošek, N. Mlčůchová, M. Cvanová, Z. Daněk, R. Kroupa, L. Bartošová, B. Lipový
520    9_
$a To this date, there are no recommendations for personalized stress ulcer prophylaxis (SUP) in critical care that would take the patient's individual genetic predispositions into account. Of drugs used for this purpose, proton pump inhibitors (PPIs) are the first-choice drugs in intensive care unit patients. The degradation of proton pump inhibitors is mediated by cytochrome P450 (CYP) enzymes; in particular, CYP2C19 and, to a lesser extent, CYP3A4 are involved. Expression and metabolic activity of, namely in, CYP2C19 is significantly affected by single nucleotide polymorphisms, the drug metabolization rate varies greatly from ultrarapid to poor and likely influences the optimal dosage. As these CYP2C19 predictive phenotypes via CYP2C19 haplogenotypes (rs12248560/rs4244285) can be relatively easily determined using the current standard equipment of hospital laboratories, we prepared a set of recommendations for personalized PPI-based stress ulcer prophylaxis taking into account the patient's CYP2C19 predictive phenotype determined in this way. These recommendations are valid, in particular, for European, American and African populations, because these populations have the high representations of the CYP2C19*17 allele associated with the overexpression of the CYP2C19 gene and ultrarapid degradation of PPIs. We propose the CYP2C19 gene profiling as a tool for personalized SUP with PPI in critically ill patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zendulka, Ondřej $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Janošek, Jaroslav $u Faculty of Medicine, Center for Health Research, University of Ostrava, Ostrava, Czechia
700    1_
$a Mlčůchová, Natálie $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia
700    1_
$a Cvanová, Michaela $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia
700    1_
$a Daněk, Zdeněk $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia $u Clinic of Maxillofacial Surgery, Faculty of Medicine, Institution Shared With University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Kroupa, Radek $u Department of Internal Medicine and Gastroenterology, Faculty of Medicine, Institution Shared With University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Bartošová, Ladislava $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Lipový, Břetislav $u Department of Burns and Plastic Surgery, Faculty of Medicine, Institution Shared With University Hospital BrnoMasaryk University, Brno, Czechia
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 9, č. - (2022), s. 854280
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35899207 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095102 $b ABA008
999    __
$a ind $b bmc $g 1854003 $s 1175029
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 9 $c - $d 854280 $e 20220711 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace